Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Colorado, Denver
With
Denver Health and Hospital Authority
National Institute on Drug Abuse (NIDA)
Gilead Sciences
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ability to give informed consent
HIV-infected men and women
Chronic HCV infection as documented by quantifiable HCV RNA
HCV genotype 1, 4, 5, 6
18-70 years of age
Willingness and ability to comply with study procedures, including DOT, WOT, and biweekly clinic visits
Considered an active drug user by HCV provider and self-reported drug use within the past month
You may not be if
Glomerular filtration rate \< 30 mL/min/1.73 m2
Receipt of prior HCV treatment and radiographic, histologic, or clinical evidence of cirrhosis
Decompensated liver disease (i.e., ascites, history of esophageal variceal bleeding, hepatic encephalopathy)
Medications not recommended per the SOF/LDV prescribing information (e.g., tipranavir and other P-gp inducers, tenofovir disoproxil fumarate plus cobicistat, rosuvastatin, amiodarone)
Any medical condition that in the opinion of the investigators will make it challenging to adhere to the study protocol, such as unstable heart disease or cancer
Chronic Hepatitis B virus Infection
For females, active pregnancy or any intent to become pregnant
For both sexes, an unwillingness to use contraception during the study period
On parole or impending sentencing
Clareo Health | Antiviral Pharmacology and Adherence in Drug Users
